遺伝子治療市場：ベクター（非ウイルス性（オリゴヌクレオチド）、ウイルス性（レトロウイルス、アデノ随伴））、適応症（癌、神経疾患、肝疾患、デュシャンヌ型筋ジストロフィー）、送達方法（In Vivo、Ex Vivo）、地域別 - 2027年までの世界市場予測

Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2027

世界の遺伝子治療市場は、2022年に推定73億米ドルと評価され、2027年には予測期間中にCAGR18.6%で172億米ドルに達すると予測されています。神経疾患や癌の症例の増加、遺伝子治療製品の認可の増加、遺伝子治療関... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年7月27日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	154	198	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の遺伝子治療市場は、2022年に推定73億米ドルと評価され、2027年には予測期間中にCAGR18.6%で172億米ドルに達すると予測されています。神経疾患や癌の症例の増加、遺伝子治療製品の認可の増加、遺伝子治療関連の研究開発への投資の増加などの要因が、市場の成長を促進しています。しかし、遺伝子治療にかかる費用が高いことなどが、この市場の成長を抑制しています。
"遺伝子治療市場において、予測期間中の適応症別では、がん分野が最も高い成長率を占めた"
2021年、癌セグメントが最も高い成長率を占めました。癌を治療するための遺伝子治療に対する需要の高まりと相まって、世界中で癌の疾病負担が増加していることが、予測期間中に癌のセグメント成長を増大させるでしょう。

「アジア太平洋地域。遺伝子治療市場で最も急速に成長している地域"
アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると推定されます。この市場の高い成長率は、新興国における医療費の改善、製品上市の増加、がんや神経疾患の発生率の増加などに起因しています。
本レポートのために実施した主なインタビューは以下のように分類されます。

- 企業タイプ別ティア1 32%, ティア2 44%, ティア3 24
- 役職別Cレベル（マネージャー） - 30%、Dレベル（CXO、ディレクター） - 34%、その他（エグゼクティブ） - 36
- 地域別北米：50％、欧州：32％、アジア太平洋：10％、その他の地域：8
報告書に掲載されている企業一覧
- バイオジェン（米国）
- サレプタ・セラピューティクス（米国）
- ギリアド・サイエンシズ社（米国）
- アムジェン社（米国）
- ノバルティスAG（スイス）
- オーチャード・セラピューティック・ピーエルシー（英国）
- スパーク・セラピューティクス社（F.ホフマン・ラ・ロシュの一部）（米国）
- AGCバイオロジクス（米国）
- 株式会社アンジェス（日本）
- ブルーバードバイオ社（米国）
- Jazz Pharmaceuticals Plc（アイルランド）
- ダイナバックス・テクノロジーズ（米国）
- ヒト幹細胞研究所（ロシア）
- シビオノジェネテック社（中国(中国)
- 上海サンウェイバイオテック社（中国(中国)
- ユニクレ N.V.（オランダ）
- Gensight Biologics S.A.（フランス）
- セルジーン・コーポレーション（ブリストル・マイヤーズスクイブ・カンパニー）（アメリカ）
- セレクティス（フランス）
- サンガモ・セラピューティック（米国）
- ムスタングバイオ（米）
- AGTC (Applied Genetic Technologies Corporation)（米国）
- ポセイド・セラピューティクス（米国）
調査対象
本レポートは、世界の遺伝子治療市場の詳細な姿を提供します。ベクター、適応症、送達方法、地域などの異なるセグメントにおける市場規模および将来の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、遺伝子治療市場全体とそのサブセグメントにおける収益数の最も近い概算を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争環境をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、課題、動向、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 23
1.1 STUDY OBJECTIVES 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS AND EXCLUSIONS 23
1.3 STUDY SCOPE 24
1.3.1 MARKETS COVERED 24
1.4 YEARS CONSIDERED 24
1.5 CURRENCY CONSIDERED 25
1.6 LIMITATIONS 25
1.7 STAKEHOLDERS 25
1.8 SUMMARY OF CHANGES 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
FIGURE 1 RESEARCH DESIGN 26
2.1.1 SECONDARY DATA 26
FIGURE 2 KEY DATA FROM SECONDARY SOURCES 27
2.1.2 PRIMARY DATA 27
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 28
2.2 MARKET SIZE ESTIMATION 28
2.2.1 BOTTOM-UP APPROACH 28
2.2.2 COMPANY REVENUE ANALYSIS 28
FIGURE 4 COMPANY REVENUE ANALYSIS 29
2.2.3 GROWTH FORECAST 29
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 30
FIGURE 5 DATA TRIANGULATION METHODOLOGY 30
2.4 RESEARCH ASSUMPTIONS 31
2.5 RISK ASSESSMENT 31
3 EXECUTIVE SUMMARY 32
FIGURE 6 GENE THERAPY MARKET, BY VECTOR, 2022 VS. 2027 (USD MILLION) 32
FIGURE 7 GENE THERAPY MARKET, BY DELIVERY METHOD,
2022 VS. 2027 (USD MILLION) 33
FIGURE 8 GENE THERAPY MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION) 33
FIGURE 9 GENE THERAPY MARKET: REGIONAL SNAPSHOT 34

4 PREMIUM INSIGHTS 35
4.1 GENE THERAPY MARKET OVERVIEW 35
FIGURE 10 HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH 35
4.2 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2021) 36
FIGURE 11 NON-VIRAL VECTORS DOMINATE NORTH AMERICAN GENE THERAPY MARKET 36
4.3 GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET 36
FIGURE 12 APAC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
FIGURE 13 GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 37
5.2.1 DRIVERS 37
5.2.1.1 High incidence of cancer and other target diseases 37
TABLE 1 NUMBER OF NEW CANCER CASES, 2020 VS. 2025 38
5.2.1.2 Product approvals 38
TABLE 2 PRODUCT APPROVALS, 2015–2021 38
5.2.1.3 Funding for gene therapy research 39
5.2.2 OPPORTUNITIES 39
5.2.2.1 Strong product pipeline 39
TABLE 3 GENE THERAPY MARKET: INDICATIVE LIST OF PIPELINE DRUGS 40
5.2.3 CHALLENGES 40
5.2.3.1 High treatment costs 40
TABLE 4 PRICE OF GENE THERAPY PRODUCTS, 2021 40
5.3 PRICING ANALYSIS 41
5.4 TECHNOLOGY ANALYSIS 41
FIGURE 14 KEY STEPS IN GENE THERAPY 41
5.5 SUPPLY CHAIN ANALYSIS 42
5.5.1 PROMINENT COMPANIES 42
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES (SMES) 42
5.5.3 END USERS 42
FIGURE 15 GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS 42
5.6 ECOSYSTEM ANALYSIS OF GENE THERAPY MARKET 43
TABLE 5 STAKEHOLDERS IN THE GENE THERAPY ECOSYSTEM AND THEIR ROLES 43
5.7 KEY CONFERENCES AND EVENTS IN 2022–2023 44
TABLE 6 GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 44
5.8 REGULATORY ANALYSIS 45
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 45
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 45
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 46
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 46
5.9 PORTER’S FIVE FORCES ANALYSIS 46
TABLE 11 GENE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 46
5.9.1 THREAT OF NEW ENTRANTS 47
5.9.2 THREAT OF SUBSTITUTES 47
5.9.3 BARGAINING POWER OF SUPPLIERS 47
5.9.4 BARGAINING POWER OF BUYERS 47
5.9.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 47
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 47
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 47
FIGURE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GENE THERAPY PRODUCTS 47
5.10.2 BUYING CRITERIA FOR GENE THERAPY PRODUCTS 48
FIGURE 17 KEY BUYING CRITERIA FOR END USERS 48
6 GENE THERAPY MARKET, BY VECTOR 49
6.1 INTRODUCTION 50
TABLE 12 GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 50
6.2 NON-VIRAL VECTORS 50
TABLE 13 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION,
2020–2027 (USD MILLION) 50
TABLE 14 GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 51
6.2.1 OLIGONUCLEOTIDES 51
6.2.1.1 Oligonucleotides account for the largest share of the non-viral vectors market 51
TABLE 15 GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION,
2020–2027 (USD MILLION) 51
6.2.2 OTHER NON-VIRAL VECTORS 52
TABLE 16 GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION) 52
6.3 VIRAL VECTORS 52
TABLE 17 GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION,
2020–2027 (USD MILLION) 52
TABLE 18 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 53
6.3.1 RETROVIRAL VECTORS 53
TABLE 19 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION,
2020–2027 (USD MILLION) 53
TABLE 20 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 53

6.3.1.1 Gamma-retroviral vectors 54
6.3.1.1.1 Availability of wide range of gamma-retroviral vectors supports market growth 54
TABLE 21 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2020–2027 (USD MILLION) 54
6.3.1.2 Lentiviral vectors 54
6.3.1.2.1 North America to dominate lentiviral vectors market 54
TABLE 22 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION,
2020–2027 (USD MILLION) 54
6.3.2 ADENO-ASSOCIATED VIRUS VECTORS 55
6.3.2.1 Potential applications in in vivo applications to drive interest in AAV vectors 55
TABLE 23 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION,
2020–2027 (USD MILLION) 55
6.3.3 OTHER VIRAL VECTORS 55
TABLE 24 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION,
2020–2027 (USD MILLION) 55
7 GENE THERAPY MARKET, BY INDICATION 56
7.1 INTRODUCTION 57
TABLE 25 GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 57
7.2 NEUROLOGICAL DISEASES 57
7.2.1 NEUROLOGICAL DISEASES TO FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET 57
TABLE 26 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION,
2020–2027 (USD MILLION) 58
7.3 CANCER 58
7.3.1 GROWING DEMAND FOR CANCER THERAPIES TO DRIVE MARKET GROWTH 58
TABLE 27 NUMBER OF NEW CANCER CASES, BY TYPE, 2020–2040 58
TABLE 28 GENE THERAPY MARKET FOR CANCER, BY REGION,
2020–2027 (USD MILLION) 59
7.4 DUCHENNE MUSCULAR DYSTROPHY 60
7.4.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH 60
TABLE 29 GENE THERAPY MARKET FOR DMD, BY REGION, 2020–2027 (USD MILLION) 60
7.5 HEPATOLOGICAL DISEASES 60
7.5.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS TO SUPPORT MARKET GROWTH 60
TABLE 30 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION,
2020–2027 (USD MILLION) 60
7.6 OTHER INDICATIONS 61
TABLE 31 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2020–2027 (USD MILLION) 61

8 GENE THERAPY MARKET, BY DELIVERY METHOD 62
8.1 INTRODUCTION 63
TABLE 32 GENE THERAPY MARKET, BY DELIVERY METHOD, 2020–2027 (USD MILLION) 63
8.2 IN VIVO GENE THERAPY 63
8.2.1 IN VIVO GENE THERAPY TO DOMINATE MARKET 63
TABLE 33 IN VIVO GENE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 63
8.3 EX VIVO GENE THERAPY 64
8.3.1 EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGH GROWTH 64
TABLE 34 EX VIVO GENE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 64
9 GENE THERAPY MARKET, BY REGION 65
9.1 INTRODUCTION 66
TABLE 35 GENE THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 66
9.2 NORTH AMERICA 67
FIGURE 18 NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT 67
TABLE 36 NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 68
TABLE 37 NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR,
2020–2027 (USD MILLION) 68
TABLE 38 NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS,
BY TYPE, 2020–2027 (USD MILLION) 68
TABLE 39 NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION) 68
TABLE 40 NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 69
TABLE 41 NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 69
TABLE 42 NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 69
9.2.1 US 70
9.2.1.1 US dominates the global gene therapy market 70
TABLE 43 LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES 70
TABLE 44 US FDA GENE THERAPY PRODUCT APPROVALS 71
TABLE 45 US: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 71
TABLE 46 US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 71
TABLE 47 US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 72
TABLE 48 US: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72
TABLE 49 US: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 72
TABLE 50 US: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 72
9.2.2 CANADA 73
9.2.2.1 Growing burden of cancer supports market growth in Canada 73
TABLE 51 CANADA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 73
TABLE 52 CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION) 73
TABLE 53 CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 74
TABLE 54 CANADA: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 74
TABLE 55 CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 74
TABLE 56 CANADA: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 75
9.3 EUROPE 75
TABLE 57 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 58 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 76
TABLE 59 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 76
TABLE 60 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 76
TABLE 61 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 76
TABLE 62 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 77
TABLE 63 EUROPE: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 77
9.3.1 GERMANY 77
9.3.1.1 Germany dominates European gene therapy market 77
TABLE 64 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 77
TABLE 65 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 78
TABLE 66 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 67 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 79
TABLE 68 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 79
TABLE 69 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 79
TABLE 70 GERMANY: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 79
9.3.2 FRANCE 80
9.3.2.1 Increasing cancer incidence to support market growth 80
TABLE 71 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 80
TABLE 72 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 80
TABLE 73 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 80
TABLE 74 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 81
TABLE 75 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 81
TABLE 76 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 81
TABLE 77 FRANCE: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 81
9.3.3 UK 82
9.3.3.1 Rising incidence of melanoma to support market growth in UK 82
TABLE 78 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 82
TABLE 79 UK: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 82
TABLE 80 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 83
TABLE 81 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 83
TABLE 82 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 83
TABLE 83 UK: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 83
TABLE 84 UK: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 84
9.3.4 ITALY 84
9.3.4.1 High incidence of targeted diseases and increasing healthcare spending to drive Italian market growth 84
TABLE 85 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 84
TABLE 86 ITALY: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 84
TABLE 87 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 85
TABLE 88 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 85
TABLE 89 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 90 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 85
TABLE 91 ITALY: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 86
9.3.5 SPAIN 86
9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain 86
TABLE 92 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 86
TABLE 93 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 86
TABLE 94 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 87
TABLE 95 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 87
TABLE 96 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 97 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 87
TABLE 98 SPAIN: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 88
9.3.6 REST OF EUROPE 88
TABLE 99 ROE: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 88
TABLE 100 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 89
TABLE 101 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 89
TABLE 102 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 89
TABLE 103 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 89
TABLE 104 ROE: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 90
9.4 ASIA PACIFIC 91
FIGURE 19 ASIA PACIFIC: GENE THERAPY MARKET SNAPSHOT 91
TABLE 105 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 106 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR,
2020–2027 (USD MILLION) 92
TABLE 107 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 108 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 92
TABLE 109 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 93
TABLE 110 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 93
TABLE 111 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 93
9.4.1 JAPAN 94
9.4.1.1 Japan dominates the APAC gene therapy market 94
TABLE 112 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 94
TABLE 113 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 94
TABLE 114 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 94
TABLE 115 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 95
TABLE 116 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 95
TABLE 117 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 95
TABLE 118 JAPAN: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 95
9.4.2 CHINA 96
9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China 96
TABLE 119 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 96
TABLE 120 CHINA: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 96
TABLE 121 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 96
TABLE 122 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 97
TABLE 123 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 97
TABLE 124 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 97
TABLE 125 CHINA: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 97
9.4.3 REST OF ASIA PACIFIC 98
TABLE 126 ROAPAC: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 98
TABLE 127 ROAPAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 128 ROAPAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 98
TABLE 129 ROAPAC: RETROVIRAL VECTORS MARKET, BY TYPE,
2020–2027 (USD MILLION) 99
TABLE 130 ROAPAC: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 99
TABLE 131 ROAPAC: GENE THERAPY MARKET, BY INDICATION,
2020–2027 (USD MILLION) 99
9.5 REST OF THE WORLD 100
TABLE 132 ROW: GENE THERAPY MARKET, BY VECTOR, 2020–2027 (USD MILLION) 100
TABLE 133 ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 134 ROW: GENE THERAPY MARKET, BY DELIVERY METHOD,
2020–2027 (USD MILLION) 100
TABLE 135 ROW: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020–2027 (USD MILLION) 101
TABLE 136 ROW: RETROVIRAL VECTORS MARKET, BY TYPE, 2020–2027 (USD MILLION) 101
TABLE 137 ROW: GENE THERAPY MARKET, BY INDICATION, 2020–2027 (USD MILLION) 101
10 COMPETITIVE LANDSCAPE 102
10.1 OVERVIEW 102
FIGURE 20 KEY DEVELOPMENTS IN THE GENE THERAPY MARKET 102
10.2 MARKET SHARE ANALYSIS, 2021 103
FIGURE 21 GENE THERAPY MARKET SHARE ANALYSIS, 2021 103
TABLE 138 GENE THERAPY MARKET: DEGREE OF COMPETITION 104
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 104
FIGURE 22 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GENE THERAPY, 2019–2021 104
10.4 COMPANY EVALUATION QUADRANT 105
10.4.1 STARS 105
10.4.2 EMERGING LEADERS 105
10.4.3 PERVASIVE PLAYERS 105
10.4.4 PARTICIPANTS 105
FIGURE 23 GENE THERAPY MARKET: COMPANY EVALUATION QUADRANT, 2021 106
10.5 COMPANY FOOTPRINT ANALYSIS 107
10.5.1 PRODUCT FOOTPRINT OF COMPANIES 107
TABLE 139 GENE THERAPY MARKET: COMPANY PRODUCT FOOTPRINT (2021) ACROSS INDICATIONS 107
10.6 COMPETITIVE SCENARIO 108
TABLE 140 PRODUCT APPROVALS, 2018–2022 108
TABLE 141 DEALS, 2018–2022 108
TABLE 142 OTHER DEVELOPMENTS, 2018-2022 109
11 COMPANY PROFILES 110
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1 BIOGEN 110
TABLE 143 BIOGEN: BUSINESS OVERVIEW 110
FIGURE 24 BIOGEN: COMPANY SNAPSHOT 110
11.2 SAREPTA THERAPEUTICS 113
TABLE 144 SAREPTA THERAPEUTICS: BUSINESS OVERVIEW 113
FIGURE 25 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT 113
11.3 GILEAD SCIENCES, INC. 117
TABLE 145 GILEAD SCIENCES INC: BUSINESS OVERVIEW 117
FIGURE 26 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT 118
11.4 AMGEN, INC. 120
TABLE 146 AMGEN INC: BUSINESS OVERVIEW 120
FIGURE 27 AMGEN, INC.: COMPANY SNAPSHOT 121
11.5 NOVARTIS AG 123
TABLE 147 NOVARTIS AG: BUSINESS OVERVIEW 123
FIGURE 28 NOVARTIS AG: COMPANY SNAPSHOT 124
11.6 ORCHARD THERAPEUTICS PLC 127
TABLE 148 ORCHARD THERAPEUTICS PLC: BUSINESS OVERVIEW 127
FIGURE 29 ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT 127
11.7 SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY) 129
TABLE 149 SPARK THERAPEUTICS INC: BUSINESS OVERVIEW 129
11.8 AGC BIOLOGICS 131
TABLE 150 AGC BIOLOGICS: BUSINESS OVERVIEW 131
11.9 ANGES, INC. 132
TABLE 151 ANGES INC: BUSINESS OVERVIEW 132
FIGURE 30 ANGES, INC.: COMPANY SNAPSHOT 132
11.10 BLUEBIRD BIO, INC. 134
TABLE 152 BLUEBIRD BIO: BUSINESS OVERVIEW 134
FIGURE 31 BLUEBIRD BIO: COMPANY SNAPSHOT 134
11.11 JAZZ PHARMACEUTICALS PLC 136
TABLE 153 JAZZ PHARMACEUTICALS: BUSINESS OVERVIEW 136
FIGURE 32 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT 137
11.12 DYNAVAX TECHNOLOGIES 139
TABLE 154 DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW 139
FIGURE 33 DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT 140
11.13 HUMAN STEM CELLS INSTITUTE 141
TABLE 155 HUMAN STEM CELLS INSTITUTE: BUSINESS OVERVIEW 141
11.14 SIBIONO GENETECH CO., LTD. 142
TABLE 156 SIBIONO GENETECH CO LTD: BUSINESS OVERVIEW 142
11.15 SHANGHAI SUNWAY BIOTECH CO., LTD. 143
TABLE 157 SHANGHAI SUNWAY BIOTECH CO LTD: BUSINESS OVERVIEW 143
11.16 UNIQURE N.V. 144
TABLE 158 UNIQURE NV: BUSINESS OVERVIEW 144
11.17 GENSIGHT BIOLOGICS S.A. 145
TABLE 159 GENSIGHT BIOLOGICS SA: BUSINESS OVERVIEW 145
11.18 CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY) 146
TABLE 160 CELGENE CORPORATION: BUSINESS OVERVIEW 146
11.19 CELLECTIS 147
TABLE 161 CELLECTIS: BUSINESS OVERVIEW 147
11.20 SANGAMO THERAPEUTICS 148
TABLE 162 SANGAMO THERAPEUTICS: BUSINESS OVERVIEW 148
11.21 MUSTANG BIO 149
TABLE 163 MUSTANG BIO: BUSINESS OVERVIEW 149
11.22 AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION) 151
TABLE 164 AGTC: BUSINESS OVERVIEW 151
11.23 POSEIDA THERAPEUTICS, INC. 152
TABLE 165 POSEIDA THERAPEUTICS INC: BUSINESS OVERVIEW 152
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12 APPENDIX 153
12.1 DISCUSSION GUIDE 153
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 156
12.3 AVAILABLE CUSTOMIZATION OPTIONS 158
12.4 RELATED REPORTS 158
12.5 AUTHOR DETAILS 159

ページTOPに戻る

Table of Contents

Summary

The global gene therapy market is valued at an estimated USD 7.3 billion in 2022 and is projected to reach USD 17.2 billion by 2027, at a CAGR of 18.6% during the forecast period. Factors such asrising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth. However,factors like high cost of gene therapy is restraining the growth of this market.
“The cancer segment accounted for the highest growth ratein the gene therapy market, by indication, during the forecast period”
In 2021, cancer segment accounted for the highest growth rate. Growing disease burden of cancer across the globe coupled with rising demand for gene therapies to treat cancer will augment the segmental growth of cancer over the forecast period.

“Asia Pacific: The fastest-growing region in the gene therapy market”
The Asia Pacific market is estimated to record the highest CAGR during the forecast period. The high growth rate of this market can be attributed to the improving healthcare expenditure in emerging economies, increasing product launches, and increasing incidence of cancer and neurological diseases.
The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 32%, Tier 2- 44%, and Tier 3-24%
• By Designation: C-level (Managers) - 30%, D-level(CXOs, Directors)- 34%, and Others (Executives) - 36%
• By Region: North America -50%, Europe -32%, Asia-Pacific -10%, Rest of the World -8%
List of Companies Profiled in the Report:
• Biogen (US)
• Sarepta Therapeutics (US)
• Gilead Sciences, Inc. (US)
• Amgen, Inc. (US)
• Novartis AG (Switzerland)
• Orchard Therapeutics Plc (UK)
• Spark Therapeutics, Inc. (A Part Of ‎F. Hoffmann-La Roche) (US)
• AGC Biologics (US)
• Anges, Inc. (Japan)
• Bluebird Bio, Inc. (US)
• Jazz Pharmaceuticals Plc (Ireland)
• Dynavax Technologies (US)
• Human Stem Cells Institute (Russia)
• SibionoGenetech Co., Ltd. (China)
• Shanghai Sunway Biotech Co., Ltd. (China)
• Uniqure N.V. (Netherland)
• Gensight Biologics S.A. (France)
• Celgene Corporation (A Bristol-Myers Squibb Company) (US)
• Cellectis (France)
• Sangamo Therapeutics (US)
• Mustang Bio (US)
• AGTC (Applied Genetic Technologies Corporation) (US)
• Poseida Therapeutics, Inc. (US)
Research Coverage:
This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments such as vectors, indication, delivery method, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges,trends,and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（gene）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（gene）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?